摘要:
The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders.
摘要:
The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.
摘要:
Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.
摘要:
Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.
摘要:
The present invention relates to a composition comprising 0.1-10 w/w% immunoglobulin (Ig), 4-14 w/w% saturated fatty acids, 4-14 w/w% mono-unsaturated fatty acids and 0-5 w/w% poly-unsaturated fatty acids, wherein the weight percentages are based on the content of dry matter in the composition. In particular it relates to the use of said composition as a feed and/or a food composition.